Stockwatch: 2017, Year Of The Dog
Executive Summary
News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.
You may also be interested in...
Stockwatch: Pricing Delusions Of Blockbuster Proportions
Sales expectations for the products of companies like Acadia, BTG, Keryx and probably Sarepta remain too high, despite the bursting of the last biotech bubble. Aggressive price increases have traditionally been one way to inch closer to those expectations but that door has closed.
Stockwatch: Awkward Developments Pricking J.P. Morgan Bubble
The warm fuzzy feeling in life sciences in the week before the J.P. Morgan Healthcare Conference was rudely threatened by clinical trial results from Halozyme and Heron, and negative financial preannouncements from Heron and Teva.
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016
Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.